Pentavalent rotavirus vaccine effectiveness among children in Shenzhen, China: A population-based test-negative design with directed acyclic graphs bias adjustment

中国深圳儿童五价轮状病毒疫苗有效性:基于人群的检测阴性设计及有向无环图偏差调整

阅读:1

Abstract

BACKGROUND: China's Notifiable Disease Reporting System comprehensively collects data on pediatric acute gastroenteritis cases from all levels of healthcare. This study evaluated the effectiveness of the pentavalent rotavirus vaccine against rotavirus gastroenteritis in children under five years of age during seasonal epidemic periods. METHODS: Using a test-negative design, we analyzed laboratory data from diarrhea patients aged 2-59 months who sought medical care in Longhua District, Shenzhen, Guangdong Province, China between January 2020 and March 2024. Vaccination history and potential confounders, including sex, household registration status, prematurity, and birth weight, were collected retrospectively. Directed acyclic graphs were used to identify adjustment variables. Vaccine effectiveness was calculated as (1 - adjusted odds ratio) × 100% using unconditional logistic regression, comparing rotavirus-positive cases with rotavirus-negative controls. RESULTS: The incidence of rotavirus gastroenteritis peaked and then progressively declined from January 2020 through March 2023, with no seasonal resurgence observed in the first quarter of 2023. Analysis of 928 epidemic-season cases (674 RV+; 254 RV-) revealed an overall pentavalent rotavirus (RV5) vaccine effectiveness of 79.6% (95% CI: 68.9%-86.6%). Dose-specific vaccine effectiveness varied substantially: 1 dose vaccine effectiveness registered at 26.7% (95% CI: -162.1%-79.5%), rising to 76.6% (95% CI: 46.2%-89.8%) for 2 doses, and reaching 82.7% (95% CI: 72.2%-89.2%) for 3 doses. Age-stratified analysis showed vaccine effectiveness of 79.5% (95% CI: 56.8%-90.3%) in children aged 2-11 months, 83.8% (95% CI: 66.4%-92.2%) for 12-23 months, and 79.6% (95% CI: 68.9%-86.6%) in those aged 24-35 months, while vaccine effectiveness was 31.2% (95% CI: -251.8%-86.5%) in children aged 36-59 months. CONCLUSIONS: A three-dose regimen of pentavalent rotavirus vaccine provides significant effectiveness against rotavirus gastroenteritis for children under 36 months of age during epidemic seasons, thereby alleviating the burden on public health systems.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。